The regulatory landscape for actively personalized cancer immunotherapies
The regulatory landscape for actively personalized cancer immunotherapies
C. Britten,H. Singh-Jasuja,10 Authors,U. Kalinke
2013 · DOI: 10.1038/nbt.2708
Nature Biotechnology · 60 Citations
TLDR
Quality attributes of APVACs targeting the mutanome need to be prospectively defined as for any medicine, which will be feasible when using vaccine formats, such as synthetic peptides or RNA that can be well characterized.